NEW YORK — CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.

This month, CVS Caremark announced that it had also signed a deal to make Novo Nordisk’s Wegovy its preferred GLP-1RA ...

CVS’s drug-benefits unit, known as Caremark, earlier this month negotiated a deal to make Novo’s Wegovy more widely available to its customers — knocking Eli Lilly & Co.’s Zepbound off its ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

However, CVS Health recently announced that Wegovy will be the preferred option on its list of covered drugs starting July 1, while Zepbound won't be. “We’re going to need to use them all just ...

Shares of CVS Health Corp. CVS soared toward a one-year ... Obamacare business and will increase access to weight-loss drug Wegovy as it reported blowout earnings. The company said it decided ...

But employers and unions will ultimately determine how much of those savings on Wegovy get shared with members, CVS said. Wegovy's list price before insurance is $1,349 for a month's supply ...

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...